A Novel Anti-Parkinsonian Agent, Zonisamide, Attenuates MPTP-Induced Neurotoxicity in Mice

Ryohei Yano · Hironori Yokoyama · Hayato Kuroiwa ·
Hiroyuki Kato · Tsutomu Araki

Received: 11 November 2008 / Accepted: 19 January 2009 / Published online: 27 May 2009
© Humana Press 2009

Erratum to: J Mol Neurosci
DOI 10.1007/s12031-009-9181-z

In the original publication, the caption to Figure 6 contains a mistake in the description of parts C and D. The full caption in its correct form is as follows.

Figure 6 Immunoblotting analysis of TH (**A**, **B**) and GFAP (**C**, **D**) protein levels in the mouse striatum 1 day after zonisamide treatment. **A**, **C** Western blot analysis; GAPDH protein was detected as a house keeping protein to confirm that equal amounts of protein were loaded in each line. **B** TH protein levels were expressed as % of vehicle (mean $\pm$ SEM) using ratios to GAPDH protein levels. **D** GFAP protein levels were expressed as % of vehicle (mean $\pm$ SEM) using ratios to GAPDH protein levels. * $P < 0.05$ compared with vehicle group (Mann-Whitney U test). *Vehicle* 1% Tween 80; *ZNS(20)* zonisamide 20 mg/kg, i.p.; $n = 3$ –4 mice.

The online version of the original article can be found found at <http://dx.doi.org/10.1007/s12031-009-9181-z>.

R. Yano · H. Yokoyama · H. Kuroiwa · T. Araki (✉)
Department of Neurobiology and Therapeutics,
Graduate School and Faculty of Pharmaceutical Sciences,
The University of Tokushima,
Tokushima 770–8505, Japan
e-mail: tsuaraki@ph.tokushima-u.ac.jp

H. Kato
Department of Neurology, Organized Center of Clinical Medicine,
International University of Health and Welfare,
Tochigi, Japan